Publicaciones (22) Publicaciones de María Luisa Sánchez Lorenzo

2024

  1. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

    International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

  2. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  3. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer

    Seminars in Oncology Nursing, Vol. 40, Núm. 1

  4. Management challenges in low-grade serous ovarian cancer with a BRCA mutation

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 631-636

  5. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

  6. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  7. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2771-2782

2023

  1. Ansprechen follikulotroper Mycosis fungoides auf Capecitabin

    JDDG - Journal of the German Society of Dermatology

  2. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  3. Response of folliculotropic mycosis fungoides to capecitabine

    JDDG - Journal of the German Society of Dermatology

  4. Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

    Gynecologic Oncology Reports, Vol. 48

2022

  1. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

  2. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

  3. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

    BMC Cancer, Vol. 22, Núm. 1

  4. The BRCA Gene in Epithelial Ovarian Cancer

    Cancers, Vol. 14, Núm. 5

2021

  1. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

    International Journal of Gynecological Cancer, Vol. 31, Núm. 4, pp. 617-622

2019

  1. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?

    Cancer, Vol. 125, Núm. S24, pp. 4616-4622

  2. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2016

  1. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome It

    Clinical Medicine Insights: Oncology, Vol. 10, pp. 21-30

2014

  1. First-line and maintenance therapy for ovarian cancer: Current status and future directions

    Drugs, Vol. 74, Núm. 8, pp. 879-889